Mutations in IDH were recently described in several tumor types including glioma [4–6], acute myeloid leukemia (AML) [7–9] and as well as thyroid [10], breast adenocarcinoma [11] colorectal and prostate carcinomas, and B cell lymphoma [12]. Here, IDH2 is linked to central nervous system cancer.